Jan 28, 2025 · Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of kidney failure, which is one of the leading causes of death in the US and ...

3 days ago · FDA approves Ozempic ® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. News ...

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.

Jan 28, 2025 · The F.D.A. based its decision to expand the approved uses of Ozempic on research showing that people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower ...

Jan 28, 2025 · chronic kidney disease . Plainsboro, N.J., January 28, 2025 – Novo Nordisk today announced . that the U.S. Food and Drug Administration (FDA) has approved Ozempic® to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes

2 days ago · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD).. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial ...

Mar 8, 2024 · People with type 2 diabetes and chronic kidney disease (CKD) who took Ozempic (semaglutide) slowed the progression of kidney disease by 24% and cut their risk of death from kidney disease. Patients who took Ozempic versus placebo also cut their risk of major heart problems by 18%. The latest: Newly FDA approved for CKD, Ozempic is the first GLP ...

May 24, 2024 · Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic...

Jan 30, 2025 · The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease. This approval makes Ozempic the first GLP-1 treatment for patients with both conditions. Chronic kidney ...

Jan 28, 2025 · Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.